Systemic radionuclide therapy with strontium chloride Sr 89 for painful skeletal metastases in prostate and breast cancer.
Systemic radionuclide therapy with strontium chloride Sr 89 is a rediscovered alternative to relieve pain from bony metastases. Although numerous advances have been made in the diagnosis and treatment of cancer, pain remains a serious and debilitating disease complication. An increasing number of clinical trials are reporting satisfactory results with 89Sr-chloride therapy, now available for widespread clinical use. We have treated 11 patients with this radionuclide; of these patients, 8 had excellent to dramatic pain relief and 3 had mild to moderate improvement. Clinical response was based on subjective pain relief, increased mobility, decreased analgesic uptake, and/or improvement in daily activities, including work habits.
Patel
B R
BR
Department of Radiology, University of Mississippi Medical Center, Jackson 39216, USA.
Flowers
W M
WM
D000203:Activities of Daily Living; D001859:Bone Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000150:complications / Q000473:pathology*; D006801:Humans; D008297:Male; D010146:Pain / Q000209:etiology; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology*; D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes